Clinical Trials Directory

Trials / Completed

CompletedNCT05113602

Validation of the EEG Signal Quality Measured by the URGOnight Device and Comparison With a Clinical Device

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
35 (actual)
Sponsor
Urgotech · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

The electroencephalogram or EEG is a painless and non-invasive exploratory examination routinely performed in clinical and experimental medicine and has various applications. It is therefore relevant to develop application-specific EEG measurement devices. The clinical development of therapies based on brain control has led to the emergence of numerous EEG devices that aim to allow mobile, autonomous, and easy use for users. Data from the literature have proven the ability of neurofeedback (a form of biofeedback in which subjects respond to a display of their own brainwaves in order to improve their health or performance) to improve brain function in healthy or pathological subjects. These therapeutic applications are offered in hospital settings with conventional systems and in the presence of a therapist. The EEG measurement device URGOnight was developed with the aim of offering autonomous neurofeedback exercises at home. URGOnight is a portable device. It uses passive electrodes (which do not send an electric current) and so-called dry electrodes, i.e. no gel or conductive paste is required. Therefore, the SIGMA study aims to evaluate the quality of the EEG signal collected by URGOnight and compare it with an electroencephalography device commonly used in clinical and research settings. We will also evaluate the quality of the brain wave measurement usually retained in comparative studies of EEG systems.

Conditions

Interventions

TypeNameDescription
DEVICEURGOnightEEG dry electrodes portable device
DEVICEEnobioEEG wet electrodes portable device

Timeline

Start date
2021-01-26
Primary completion
2021-01-30
Completion
2021-06-30
First posted
2021-11-09
Last updated
2021-11-09

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05113602. Inclusion in this directory is not an endorsement.